The FDA approved Zelboraf (vemurafenib) today for the treatment of metastatic or unresectable melanoma. The drug specifically targets tumors that express BRAF V600E gene mutation, seen in a number of patients with late-stage melanoma. This has been an exciting year in the treatment of late-stage melanoma as Zelboraf is the second of the newly approved drugs to show improvement in overall survival.
For more information see the FDA News Release.
The University of Texas Medical Branch Dermatology Interest Group (UTMB DIG) is a resource for medical students interested in Dermatology as well as for dermatologists and residents.
Editors
Current Editors: Jane Onyemachi and Madelyn Schmidt
(Please email editors if there is blog-worthy news that you would like to see shared)
Past Editors: Fareen Momin, Andrea Francis, Renat Ahatov, Michael Phan, Elise Weisert, Michael Ryan, Keith Wagner, Tim Allen, Kristyna Gleghorn, Dung Mac, Alex Acosta, William Tausend, Sheila Jalalat, Rebecca Philips, Chelsea Altinger, Lindsey Hunter, Alison Wiesenthal, Leslie Scroggins, Mara Dacso, Ashley Group, Fadi Constantine, Emily Fridlington, Joslyn Witherspoon, Tasneem Poonawalla.